The inhibitory effect of metformin on myeloma proliferation appears to be not only AMPK-independent, but must be independent of metformin's insulin-sensitizing and anti-hyperglycemic effects since these effects were observed in cell-based assays. Here, INS is linked to plasma cell myeloma.